Osivax
osivax.comTotal trials
10
Active
1
Phase 3
0
Total enrollment
4,469
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Saline solution | — | — | — | — | 3 | ||
| OVX836 480µg | — | — | — | — | — | 3 |
Next readouts
- 2026-05-29
Top conditions
- Influenza9
- Coronavirus1
- Vaccine-Preventable Diseases1
Frequently asked questions about Osivax
- How many clinical trials does Osivax have on ClinicalTrials.gov?
- Osivax is listed as the lead sponsor on 10 clinical trials in ClinicalTrials.gov, 1 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Osivax's trials are in Phase 3?
- 0 of Osivax's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Osivax focus on?
- Osivax's most-studied conditions on ClinicalTrials.gov are Influenza, Coronavirus, Vaccine-Preventable Diseases.
- When are Osivax's next clinical trial readouts?
- Osivax has 1 upcoming primary-completion readout tracked here; the soonest is “Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg”, expected around 2026-05-29.